ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

HER2-positive cancers, such as certain types of ... resulted in a significant reduction in tumor volume and improved survival rates, with fractionated dosing proving more effective than a single ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Gastric cancer is associated with a poor prognosis, particularly in the ... and around one in five cases are HER2-positive. Anti-HER2 antibody trastuzumab with chemo is the standard first-line ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

The conversion to traditional approval was supported by data from the phase 3 KEYNOTE-811 study (ClinicalTrials.gov Identifier: NCT03615326), which included 698 patients with HER2-positive ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.